Login to Your Account



Amylin's Persistence Pays Off As Lilly Signs On For $435M-Plus

By Karen Young


Monday, September 23, 2002
Amylin Pharmaceuticals Inc. entered a global agreement with Eli Lilly and Co. to collaborate on the development and commercialization of Amylin's late-stage Type II diabetes candidate, AC2993, in a deal that could mean more than $435 million for the biotech company. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription